We claim:

1. Use of a therapeutic combination in the manufacture of a medicament for the treatment of a breast cancer wherein the therapeutic combination is to be administered to a mammal as a combined formulation or by alternation, and comprises a therapeutically effective amount of trastuzumab-MCC-DM1 (T-DM1), and a therapeutically effective amount of lapatinib.

2. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of the lapatinib are to be administered as a combined formulation.

3. The use of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of the lapatinib are to be administered by alternation.

4. The use of claim 3, wherein the mammal is to be administered the lapatinib and then subsequently administered trastuzumab-MCC-DM1.

5. The use of claim 2 or claim 3, wherein the therapeutic combination is to be administered at about three week intervals to a human with the breast cancer.

6. The use of claim 2 or claim 3, wherein trastuzumab-MCC-DM1 is to be administered at intervals from about one week to three weeks to a human with the breast cancer.

7. The use of any one of claims 1-7, wherein administration of the therapeutic combination results in a synergistic effect.

8. The use of any one of claims 1-7, wherein the breast cancer is a cancer expressing ErbB2.

9. The use of any one of claims 1-8, wherein the amount of trastuzumab-MCC-DM1 and the amount of the lapatinib are each from about 1 mg to about 1000 mg.

10. The use of any one of claims 1-9, wherein the amount of trastuzumab-MCC-DM1 and the amount of the lapatinib are in a ratio of about 1:10 to about 10:1 by weight.

11. The use of any one of claims 1-10, wherein the mammal is a HER2 positive patient.

12. The use of claim 11, wherein the HER2 positive patient has received trastuzumab or lapatinib therapy.

13. A pharmaceutical composition comprising trastuzumab-MCC-DM1, lapatinib, and one or more pharmaceutically acceptable carrier, glidant, diluent, or excipient.

14. The pharmaceutical composition of claim 13, comprising a pharmaceutically acceptable glidant selected from silicon dioxide, powdered cellulose, microcrystalline cellulose, metallic stearates, sodium aluminosilicate, sodium benzoate, calcium carbonate, calcium silicate, corn starch, magnesium carbonate, asbestos free talc, stearowet C, starch, starch 1500, magnesium lauryl sulfate, magnesium oxide, and combinations thereof.

15. The pharmaceutical composition of claim 13 or claim 14, wherein the amount of trastuzumab-MCC-DM1 and the amount of the lapatinib are each present from about 1 mg to about 1000 mg.

16. The pharmaceutical composition of any one of claims 13-15, wherein the amount of trastuzumab-MCC-DM1 and the amount of the lapatinib are present in a ratio of about 1:10 to about 10:1 by weight.